Delgocitinib cream, an investigational topical pan-Janus kinase inhibitor, has demonstrated superiority to alitretinoin capsules in the treatment of severe chronic hand eczema. In a phase 3 study, delgocitinib cream achieved better outcomes in reducing hand eczema severity, improving quality of life, and experiencing fewer adverse events compared to alitretinoin capsules. Currently, delgocitinib cream is not approved for use by any health administrations, but if approved, it will provide dermatologists with evidence-based data to support treatment decisions for patients with moderate to severe chronic hand eczema.
Source link
Delgocitinib cream outperforms alitretinoin capsule in treating severe chronic hand eczema
